Mounjaro vs Ozempic
Side-by-side comparison of Mounjaro (tirzepatide (T2D injection)) and Ozempic (semaglutide (T2D injection)) across efficacy, food restrictions, monthly cost, and Medicare Bridge coverage.
Ozempic
Based on the data below, Ozempic wins on lower cash price ($998/mo vs $1069/mo). Your situation may differ — try the personalized matcher on the homepage or compute your real out-of-pocket with the cost calculator on each medication's detail page.
Mounjaro
tirzepatide (T2D injection) · Eli Lilly and Company
| Field | Mounjaro | Ozempic |
|---|---|---|
| Route | injection · weekly | injection · weekly |
| Avg weight loss | 12–16% | 5–8% |
| Food restriction | No food restriction | No food restriction |
| Cash from | $1069/mo | $998/mo |
| Savings card | — | — |
| Medicare Bridge | Tier 4 | Tier 4 |
| A1c reduction | −2.4% | −1.8% |
| FDA approved | 2022-05 | 2017-12 |
- RouteMounjaroinjection · weeklyOzempicinjection · weekly
- Avg weight lossMounjaro12–16%Ozempic5–8%
- Food restrictionMounjaroNo food restrictionOzempicNo food restriction
- Cash fromMounjaro$1069/moOzempic$998/mo
- Savings cardMounjaro—Ozempic—
- Medicare BridgeMounjaroTier 4OzempicTier 4
- A1c reductionMounjaro−2.4%Ozempic−1.8%
- FDA approvedMounjaro2022-05Ozempic2017-12
Pick Mounjaro if…
- You can't reliably do a fasting window before meds
- You want the higher peak efficacy (16% vs 8%)
Pick Ozempic if…
- You can't reliably do a fasting window before meds
- Cash pay matters more than peak weight loss ($998/mo cheaper)
Not sure which fits?
The 30-second matcher on the homepage scores every 2026 GLP-1 against your goals + preferences and recommends the best fit.